SEARCH

SEARCH BY CITATION

References

  • Akaike, H. (1974) A new look at the statistical model identification. IEEE Transactions on Automatic Control, 19, 716723.
  • Alizadeh, A.A., Eisen, M.B., Davis, R.E., Ma, C., Lossos, I.S., Rosenwald, A., Boldrick, J.C., Sabet, H., Tran, T., Yu, X., Powell, J.I., Yang, L., Marti, G.E., Moore, T., Hudson, Jr, J., Lu, L., Lewis, D.B., Tibshirani, R., Sherlock, G., Chan, W.C., Greiner, T.C., Weisenburger, D.D., Armitage, J.O., Warnke, R., Levy, R., Wilson, W., Grever, M.R., Byrd, J.C., Botstein, D., Brown, P.O. & Staudt, L.M. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 403, 503511.
  • Balducci, L. & Beghe, C. (2001) Cancer and age in the USA. Critical Reviews in Oncology/Hematology, 37, 137145.
  • Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235242.
  • Feugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R., Ferme, C., Christian, B., Lepage, E., Tilly, H., Morschhauser, F., Gaulard, P., Salles, G., Bosly, A., Gisselbrecht, C., Reyes, F. & Coiffier, B. (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. Journal of Clinical Oncology, 23, 41174126.
  • Fisher, R.I., Gaynor, E.R., Dahlberg, S., Oken, M.M., Grogan, T.M., Mize, E.M., Glick, J.H., Coltman, Jr, C.A. & Miller, T.P. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. New England Journal of Medicine, 328, 10021006.
  • Gönen, M. & Heller, G. (2005) Concordance probability and discriminative power of proportional hazards regression. Biometrika, 92, 965970.
  • Habermann, T.M., Weller, E.A., Morrison, V.A., Gascoyne, R.D., Cassileth, P.A., Cohn, J.B., Dakhil, S.R., Woda, B., Fisher, R.I., Peterson, B.A. & Horning, S.J. (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. Journal of Clinical Oncology, 24, 31213127.
  • Harrell, Jr, F.E. (2001) Regression Modeling Strategies. Springer, New York.
  • Harris, N.L., Jaffe, E.S., Diebold, J., Flandrin, G., Muller-Hermelink, H.K., Vardiman, J., Lister, T.A. & Bloomfield, C.D. (2000) The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology, 36, 6986.
  • Heagerty, P.J. & Zheng, Y. (2005) Survival model predictive accuracy and ROC curves. Biometrics, 61, 92105.
  • Janssen-Heijnen, M.L., Van Spronsen, D.J., Lemmens, V.E., Houterman, S., Verheij, K.D. & Coebergh, J.W. (2005) A population-based study of severity of comorbidity among patients with non-Hodgkin’s lymphoma: prognostic impact independent of International Prognostic Index. British Journal of Haematology, 129, 597606.
  • Kaplan, E. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457481.
  • Lenz, G., Wright, G., Dave, S.S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., Vose, J., Bast, M., Fu, K., Weisenburger, D.D., Greiner, T.C., Armitage, J.O., Kyle, A., May, L., Gascoyne, R.D., Connors, J.M., Troen, G., Holte, H., Kvaloy, S., Dierickx, D., Verhoef, G., Delabie, J., Smeland, E.B., Jares, P., Martinez, A., Lopez-Guillermo, A., Montserrat, E., Campo, E., Braziel, R.M., Miller, T.P., Rimsza, L.M., Cook, J.R., Pohlman, B., Sweetenham, J., Tubbs, R.R., Fisher, R.I., Hartmann, E., Rosenwald, A., Ott, G., Muller-Hermelink, H.K., Wrench, D., Lister, T.A., Jaffe, E.S., Wilson, W.H., Chan, W.C. & Staudt, L.M. (2008) Stromal gene signatures in large-B-cell lymphomas. New England Journal of Medicine, 359, 23132323.
  • Malumbres, R., Chen, J., Tibshirani, R., Johnson, N.A., Sehn, L.H., Natkunam, Y., Briones, J., Advani, R., Connors, J.M., Byrne, G.E., Levy, R., Gascoyne, R.D. & Lossos, I.S. (2008) Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood, 111, 55095514.
  • Monti, S., Savage, K.J., Kutok, J.L., Feuerhake, F., Kurtin, P., Mihm, M., Wu, B., Pasqualucci, L., Neuberg, D., Aguiar, R.C., Dal Cin, P., Ladd, C., Pinkus, G.S., Salles, G., Harris, N.L., Dalla-Favera, R., Habermann, T.M., Aster, J.C., Golub, T.R. & Shipp, M.A. (2005) Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood, 105, 18511861.
  • Morrison, V.A., Weller, E.A., Habermann, T.M., Cassileth, P.A., Cohn, J.B., Gascoyne, R.D., Woda, B., Fisher, R.I., Peterson, B.A. & Horning, S.J. (2007) Maintenance rituximab (MR) compared to observation (OBS) after R-CHOP or CHOP in older patients (pts) with diffuse large B-cell lymphoma (DLBCL): an Intergroup E4494/C9793 update. Journal of Clinical Oncology, 2007 Annual Meeting Proceedings Part 1, 25. No. 18S: 8011
  • Moskowitz, C., Hamlin, P.A., Horwitz, S., Noy, A., O’Connor, O., Palomba, M., Portlock, C., Straus, D., Chennin-Lessac, S., Weaver, A., Teruva-Feldstein, J., Schoder, H. & Zelenetz, A. (2006) Phase II trial of dose-dense R-CHOP followed by risk-adapted consolidation with either ICE or ICE and ASCT, based upon the results of biopsy confirmed abnormal interim restaging PET scan, improves outcome in patients with advanced stage DLBCL. Blood, 108, 532a.
  • Nyman, H., Adde, M., Karjalainen-Lindsberg, M.L., Taskinen, M., Berglund, M., Amini, R.M., Blomqvist, C., Enblad, G. & Leppa, S. (2007) Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood, 109, 49304935.
  • Pfreundschuh, M., Trumper, L., Osterborg, A., Pettengell, R., Trneny, M., Imrie, K., Ma, D., Gill, D., Walewski, J., Zinzani, P.L., Stahel, R., Kvaloy, S., Shpilberg, O., Jaeger, U., Hansen, M., Lehtinen, T., Lopez-Guillermo, A., Corrado, C., Scheliga, A., Milpied, N., Mendila, M., Rashford, M., Kuhnt, E. & Loeffler, M. (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncology, 7, 379391.
  • Pfreundschuh, M., Schubert, J., Ziepert, M., Schmits, R., Mohren, M., Lengfelder, E., Reiser, M., Nickenig, C., Clemens, M., Peter, N., Bokemeyer, C., Eimermacher, H., Ho, A., Hoffmann, M., Mertelsmann, R., Trumper, L., Balleisen, L., Liersch, R., Metzner, B., Hartmann, F., Glass, B., Poeschel, V., Schmitz, N., Ruebe, C., Feller, A.C. & Loeffler, M. (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncology, 9, 105116.
  • Repetto, L., Fratino, L., Audisio, R.A., Venturino, A., Gianni, W., Vercelli, M., Parodi, S., Dal Lago, D., Gioia, F., Monfardini, S., Aapro, M.S., Serraino, D. & Zagonel, V. (2002) Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group Performance Status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. Journal of Clinical Oncology, 20, 494502.
  • Rosenwald, A., Wright, G., Chan, W.C., Connors, J.M., Campo, E., Fisher, R.I., Gascoyne, R.D., Muller-Hermelink, H.K., Smeland, E.B., Giltnane, J.M., Hurt, E.M., Zhao, H., Averett, L., Yang, L., Wilson, W.H., Jaffe, E.S., Simon, R., Klausner, R.D., Powell, J., Duffey, P.L., Longo, D.L., Greiner, T.C., Weisenburger, D.D., Sanger, W.G., Dave, B.J., Lynch, J.C., Vose, J., Armitage, J.O., Montserrat, E., Lopez-Guillermo, A., Grogan, T.M., Miller, T.P., LeBlanc, M., Ott, G., Kvaloy, S., Delabie, J., Holte, H., Krajci, P., Stokke, T. & Staudt, L.M. (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 19371947.
  • Sehn, L.H., Donaldson, J., Chhanabhai, M., Fitzgerald, C., Gill, K., Klasa, R., MacPherson, N., O’Reilly, S., Spinelli, J.J., Sutherland, J., Wilson, K.S., Gascoyne, R.D. & Connors, J.M. (2005) Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. Journal of Clinical Oncology, 23, 50275033.
  • Sehn, L.H., Berry, B., Chhanabhai, M., Fitzgerald, C., Gill, K., Hoskins, P., Klasa, R., Savage, K.J., Shenkier, T., Sutherland, J., Gascoyne, R.D. & Connors, J.M. (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood, 109, 18571861.
  • Sonneveld, P., Wim van, P., Biesma, D., Holte, H., Van Marwijk Kooij, M., Kramer, M., Wijermans, P., Steijaert, M., VanImhoff, G., Lugtenburg, P., Huijgens, P. & Eriksson, E. (2006) Phase III trial of 2-weekly CHOP with rituximab for aggressive B-cell non-Hodgkin s lymphoma in elderly patients. Blood, 108, 210a.
  • The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. New England Journal of Medicine, 329, 987994.
  • Tirelli, U., Balzarotti, M., Uziel, L., Ferreri, A., Fratino, L., Santoro, A. & Spina, M. (2007) Comprehensive geriatric assessment (CGA)-adapted chemotherapy (CT) in elderly patients (>70 years) with diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL). Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings 25, No 18S: 19515.
  • Winter, J.N., Weller, E.A., Horning, S.J., Krajewska, M., Variakojis, D., Habermann, T.M., Fisher, R.I., Kurtin, P.J., Macon, W.R., Chhanabhai, M., Felgar, R.E., Hsi, E.D., Medeiros, L.J., Weick, J.K., Reed, J.C. & Gascoyne, R.D. (2006) Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood, 107, 42074213.
  • Yancik, R., Wesley, M.N., Ries, L.A., Havlik, R.J., Long, S., Edwards, B.K. & Yates, J.W. (1998) Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer, 82, 21232134.
  • Ziepert, M., Hasenclever, D., Kuhnt, E., Glass, B., Schmitz, N., Pfreundschuh, M. & Loeffler, M. (2010) Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. Journal of Clinical Oncology, 28, 23732380.